Pharmesis International (SGX:BFK) wholly owned subsidiary, Chengdu Kinna Pharma entered into a conditional sale and purchase agreement to acquire the remaining 19% equity interest in Sichuan Longlife Pharma from Chengdu Kinna Investment, a filing with the Singapore Exchange said on Monday.
The aggregate consideration payable by the group is 2.8 million yuan.
The acquisition is based on projections that Sichuan Longlife will secure a new procurement contract of herbal products from a new customer which could make the company profitable next year.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。